'Leadership is about understanding how a business works, how it is shaped, built, and expanded.'
'We recently launched Yesintek in the immunology space.'
Drawing lessons from security protocols of Parliament, the state is working closely with agencies like the Defence Research and Development Organisation and the Electronics Corporation of India Ltd to design a multi-layered safety mechanism.
The Supreme Court of India has dismissed a petition filed by an NGO challenging the construction of a renewable energy project at the Jayakwadi Dam in Maharashtra. The court criticized the NGO for opposing the project, stating that it would be detrimental to the country's progress if every project was resisted. The court also raised questions about the NGO's bona fides and funding, suggesting that it may have been influenced by a company that lost the tender for the project. The project, a floating solar power plant, was approved by the National Green Tribunal (NGT) and the Ministry of Environment, Forests and Climate Change. The NGT had previously dismissed the NGO's plea, stating that it could not find any law prohibiting such activities in the eco-sensitive zone. The Supreme Court upheld the NGT's decision, finding no grounds to interfere.
India and the visiting US officials have decided to hold a wrap-up session on Saturday morning to conclude the three-day talks on the proposed bilateral trade agreement, government sources said. They said the discussions are at a "very" early stage.
'We have to keep knocking on it before we get a response.'
Pakistan is allegedly working on an offensive chemical and biological warfare program with the help of its 'all-weather friend' China.
According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin.
The teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad.
The warship is packed with a plethora of sophisticated sensors, modern radar and weapons systems such as surface-to-surface missiles and surface-to-air missiles, according to the Indian Navy.
This is an important milestone that paves the way for bringing the company's single-dose COVID-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E Limited, the statement added.
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
For the first time in two years, schools in the national capital will reopen completely in offline mode from April 1 with the hybrid mode of operation coming to an end.
This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.
He congratulated the company's management on its science and innovation platform.
Invest in quality companies that make profits, advises stock market expert and rediffGURU Samraat Jadhav.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
Efforts are being ramped up for massive production of vaccines and make them available in the shortest possible time, a top government official said on Wednesday, stressing that India currently has a promising pipeline of four-five Covid-19 vaccine candidates, while three have already been approved for emergency use.
The mission objective is to ensure data continuity of ocean color and wind vector data to sustain the operational applications.
This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.
Prominent in the DRDO's display are several artillery guns, armoured vehicles and tanks that underline a measure of success in developing these key weapons platforms for the army. Here are three systems that are headed for success.
Microsoft Chairman and CEO Satya Nadella along with Alphabet Inc and its subsidiary Google CEO Sundararajan Pichai are also among those from trade and industry who have been awarded the Padma Bhushan for their distinguished services.
INS Vishakapatnam's ground attack and anti-ship capabilities are achieved through a bank of BrahMos cruise missiles that can be fired at targets up to 295 km away.
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.
'The deaths of the children in the Gambia would batter India's reputation as the developing world's pharmacy.'
The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS in New Delhi on Thursday, with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
Over the last four days, the Indian arm of US pharmaceutical giant Pfizer, Pune-based Serum Institute of India and Hyderabad-based pharmaceutical firm Bharat Biotech have applied to the Drugs Controller General of India seeking emergency use authorisation for their COVID-19 vaccines.
Phase-I clinical trials have revealed "excellent safety" of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd and their immunogenicity testing is now in progress, minister of state for health Ashwini Choubey informed the Rajya Sabha on Tuesday.
The modalities of COVID-19 vaccine delivery, distribution and administration were discussed during the meeting.
University of Madras offers many programmes from the Department of Zoology. "How to Apply" details found inside.
'The prioritisation of groups for COVID-19 vaccine shall be based on two key considerations -- occupational hazard and risk of exposure to infection, and the risk of developing severe disease and increased mortality'
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
More than 2 million people have been diagnosed with coronavirus across the world, and the pharmaceutical industry is pulling out all stops to find potential treatments and vaccines for the global pandemic. According to the World Health Organization, there are now more than 70 potential vaccines under evelopment, with some already in clinical trials.
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.
Biotechnology major Biocon India Ltd plans to invest over Rs 500 crore on its expansion plans over the next two years.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances